Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials

 Abstract

Multiple Myeloma is a molecularly heterogeneous disease with a high degree of genomic instability in which specific genetic changes can be linked to clinical presentation and prognosis. Despite recent improvements in event-free survival and overall survival with the use of high dose chemotherapy and stem cell support as well as the development of novel agents such as thalidomide, lenalidomide and Bortezomib, MM remains an incurable disease. The development of effective targeted therapies requires a detailed knowledge of various genetic and signaling pathways governing MM genesis. This review will focus on the current understanding of the molecular pathogenesis of MM and the intracellular signaling pathways and their regulations, with emphasis on the rationale for identifying therapeutic targets that can be applied in the clinic.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
830 - 838
doi
10.4161/cbt.10.9.13622
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials